ReviewCancer journal (Sudbury, Mass.)
Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.
Review in Cancer journal (Sudbury, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of metastasis-directed therapy for oligometastatic cancer: a systematic review and meta-analysis of randomized controlled trials.Radiation oncology (London, England) · 2026Pooled it
- Article
- The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial.Clinical and translational radiation oncology · 2026Article
- Oligometastatic Bladder Cancer: Current Definitions, Diagnostic Challenges, and Evolving Therapeutic Strategies.Cancers · 2026Review
- Review
- A scoping review of factors influencing the implementation of liquid biopsy for cancer care.Journal of experimental & clinical cancer research : CR · 2025Article
- Tumor heterogeneity and clinically invisible micrometastases in metastatic breast cancer-a call for enhanced surveillance strategies.NPJ precision oncology · 2024Article
- Circulating tumor DNA analysis guiding adjuvant treatment in resected stage III cholangiocarcinoma: a case report.Journal of gastrointestinal oncology · 2024Article
- Node Oligorecurrence in Prostate Cancer: A Challenge.Cancers · 2023Review
- Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.Seminars in radiation oncology · 2023Review
- Review
- Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic niche.Nature communications · 2022Article
- The Road to Dissemination: The Concept of Oligometastases and the Barriers for Widespread Disease.Cancers · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Oligometastasis represents an intermediate disease stage between localized and widely metastatic cancer. Efficient identification of patients with oligometastasis remains a barrier for accrual on clinical trials of oligometastasis-directed therapy. Here we review the prospect of circulating tumor DNA-based monitoring to promote sensitive, specific, and cost-efficient detection of cancer recurrence during posttreatment surveillance. Thus, an impetus for the development and implementation of clinical-grade circulating tumor DNA assays should be for the positive impact they will have on clinical investigations of oligometastasis-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.